<DOC>
	<DOC>NCT00563927</DOC>
	<brief_summary>To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.</brief_summary>
	<brief_title>Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Undifferentiated or nonkeratinizing carcinoma Tumor staged as N23 No evidence of distant metastasis M0 Performance status:02 Marrow: WBC &gt;= 4 and platelet &gt;= 100 Renal: creatinine clearance &gt;= 60 Informed consent WHO type I squamous cell carcinoma or adenocarcinoma Age &gt;= 70 Palliative intent or tumor extent mandating AP opposing faciocervical fields Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been diseasefree for 5 years Previous radiotherapy (except nonmelanomatous skin cancers outside the intended RT treatment volume Previous chemotherapy Patient is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>T1-4N2-3M0</keyword>
</DOC>